Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Augmentin: laboratory studies.

I D Farrell, P J Turner

    Scottish Medical Journal
    |January 1, 1982
    PubMed
    Summary
    This summary is machine-generated.

    Clavulanic acid, a beta-lactam antibiotic, inhibits bacterial beta-lactamases. Combined with amoxicillin as Augmentin, it effectively treats infections caused by resistant bacteria like Staphylococcus aureus and Haemophilus influenzae.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Emergency treatment of peri-operative anaphylaxis: Resuscitation Council UK algorithm for anaesthetists.

    Anaesthesia·2024
    Same author

    Pre-existing influenza-specific nasal IgA or nasal viral infection does not affect live attenuated influenza vaccine immunogenicity in children.

    Clinical and experimental immunology·2020
    Same author

    Comment on 'Four-year data from use of the nut and soya allergy testing protocol before treatment with isotretinoin and alitretinoin'.

    Clinical and experimental dermatology·2020
    Same author

    The risk of Kawasaki disease after pneumococcal conjugate & meningococcal B vaccine in England: A self-controlled case-series analysis.

    Vaccine·2020
    Same author

    Differences in nasal immunoglobulin A responses to influenza vaccine strains after live attenuated influenza vaccine (LAIV) immunization in children.

    Clinical and experimental immunology·2019
    Same author

    Logarithmic Upturn in Low-Temperature Electronic Transport as a Signature of d-Wave Order in Cuprate Superconductors.

    Physical review letters·2019
    Same journal

    Association of inflammation with sex hormones and vitamin D in women: Findings from NHANES (2021-2023).

    Scottish medical journal·2026
    Same journal

    The future of large language models in clinical and academic medicine.

    Scottish medical journal·2026
    Same journal

    ICDMS: Integrating multimodal data for intelligent clinical decision-making in healthcare: Current trends and future directions.

    Scottish medical journal·2026
    Same journal

    Evaluation of large language models with clinical guidance for vetting outpatient magnetic resonance imaging lumbar spine referrals.

    Scottish medical journal·2026
    Same journal

    Improving access and reducing patient travel burden through telehealth: A quality improvement report from NHS Scotland.

    Scottish medical journal·2026
    Same journal

    Scottish Cardiac Society 34th Annual General Meeting Thursday 2 & Friday 3 October 2025.

    Scottish medical journal·2026
    See all related articles

    Area of Science:

    • Microbiology
    • Pharmacology
    • Infectious Diseases

    Background:

    • Clavulanic acid is a beta-lactam antibiotic with minimal intrinsic activity.
    • It acts as a potent inhibitor of bacterial beta-lactamases, enzymes that degrade beta-lactam antibiotics.
    • Beta-lactamase production is a key mechanism of bacterial resistance to antibiotics.

    Purpose of the Study:

    • To evaluate the spectrum of activity of clavulanic acid when combined with amoxicillin (Augmentin).
    • To identify bacterial strains sensitive or resistant to Augmentin, particularly those producing beta-lactamases.

    Main Methods:

    • The study assessed the in vitro activity of the amoxicillin-clavulanic acid combination against various bacterial species.
    • Sensitivity testing was performed on strains including Staphylococcus aureus, Haemophilus influenzae, Escherichia coli, and several Gram-negative bacilli.

    Related Experiment Videos

    Main Results:

    • Augmentin demonstrated activity against penicillinase-producing Staphylococcus aureus and many beta-lactamase-producing Gram-negative bacilli.
    • Amoxicillin-resistant strains of Haemophilus influenzae and Escherichia coli were sensitive to Augmentin.
    • Bacteria like Enterobacter spp., Proteus morgani, Serratia marcescens, and Pseudomonas aeruginosa showed resistance due to less susceptibility to clavulanic acid.

    Conclusions:

    • Amoxicillin-clavulanic acid (Augmentin) broadens the spectrum of amoxicillin to include many beta-lactamase-producing bacteria.
    • Certain bacteria possess beta-lactamases less susceptible to clavulanic acid, leading to resistance.
    • This combination is valuable for treating infections caused by specific resistant bacterial strains.